Results 1 to 10 of about 54,679 (264)

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma. [PDF]

Front Endocrinol (Lausanne)
Hasan M, Samlowski W, Nakhle S.
europepmc   +1 more source

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis. [PDF]

Acta Oncol
Caeyman A, Mammone G, Kinget L, Baldewijns M, De Wever L, Albersen M, Debruyne PR, Demeulenaere O, McTaggart ES, Saraswat S, Berghen C, De Meerleer G, Naulaerts S, Garg AD, Beuselinck B.   +14 more
europepmc   +1 more source

Thyroid storm triggered by immune checkpoint inhibitor therapy. [PDF]

BMJ Case Rep
Hagiwara J, Sekine M, Sakawaki E, Sakawaki S, Takeyama Y.   +4 more
europepmc   +1 more source

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

New England Journal of Medicine, 2017
J. Weber, M. Mandalà, M. Del Vecchio, H. Gogas, A. Arance, L. Cowey, S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Márquez-Rodas, J. Grob, M. Butler, M. Middleton, M. Maio, V. Atkinson, P. Queirolo, R. Gonzalez, R. Kudchadkar, M. Smylie, N. Meyer, L. Mortier, M. Atkins, G. Long, S. Bhatia, C. Lebbé, P. Rutkowski, K. Yokota, N. Yamazaki, T. M. Kim, V. de Pril, J. Sabater, A. Qureshi, J. Larkin, P. Ascierto   +33 more
semanticscholar   +1 more source

Combined Nivolumab and Ipilimumab Therapy Promotes Immune-Mediated Cardiomyocyte Apoptosis Through TLR4-Myd88-NF-<i>Κ</i>b-Driven Activation of the NLRP3 Inflammasome. [PDF]

Hum Mutat
Gao M, Liu X, Wu L, Jiang Y, Yu J, Zhang Y.   +5 more
europepmc   +1 more source

Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report. [PDF]

Am J Case Rep
Vromans AM, Constantinou M.
europepmc   +1 more source

Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial. [PDF]

ESMO Gastrointest Oncol
Overman MJ, McCraith S, He B, Jin L, Lei M, Yao J, Morse MA.   +6 more
europepmc   +1 more source

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). [PDF]

Future Oncol
Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Matilla Peña A, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M.   +27 more
europepmc   +1 more source

Complete response to immune checkpoint blockade in sarcomatoid renal cell carcinoma with bone marrow metastasis: case report with tumor immune microenvironment profiling. [PDF]

J Immunother Cancer
Miura Y, Jikuya R, Saijo A, Yano H, Kinowaki K, Takemura K, Uchino K, Hasumi H, Komohara Y.   +8 more
europepmc   +1 more source

Correction: Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors. [PDF]

Front Immunol
Alsaafeen BH, Ali BR, Elkord E.
europepmc   +1 more source